ABSTRACTDuring cell culture, trypsin, a serine protease, is applied to cells for 5-10 minutes to separate them from each other and from the underlying substratum so that they can be transferred to a different vessel, for re-plating, after growth medium containing 10 % serum has been added to the cells, in a well-known technique known as ‘passaging’. The serum in the growth medium contains alpha-1 antitrypsin, which is a potent inhibitor of trypsin, elastase and other serine proteases. Although what is used is bovine serum in which levels of proteins could be different from levels seen in humans, normal human serum contains A1AT (> 1 mg/ml; > ∼18 µmol/L) as well as trypsin itself (< 460 ng/ml, or ∼0.02 µmol/L), with the former in a ∼900-fold molar excess over the latter. Thus, it may be assumed there is also enough A1AT in the bovine serum added during passaging, to neutralize the trypsin (∼100 μM) present in the small volume of trypsin-EDTA solution used to separate cells. What are the consequences of not adding serum, when growth medium is added, or of maintaining cells for a few tens of hours in the presence of trypsin, in a serum-free growth medium? What does such sustained exposure to trypsin during cell culture do to cells? More generally, what are the responses of cells within an organism to the balance of trypsin and A1AT in the serum that bathes them constantly? We know that excesses and deficiencies in the levels of either trypsin or A1AT are associated with disease. We know that cellular metabolism can be influenced through signaling involving protease activated membrane GPCR receptors (PAR1-4). In particular, we know of a receptor called PAR2, which is specifically activated by trypsin, expressed by cells at baseline levels, and upregulated through some feedback involving trypsin-activation. We also know that cells at sites of injury or inflammation produce and secrete trypsin, and that this trypsin can act locally upon cells in a variety of ways, all of which have probably not yet been elucidated. Here, we show that sustained exposure to trypsin induces cells to de-differentiate into a stem-like state. We show that if serum is either not added at all, or added and then washed away (after confluency is attained), during cell culture, all cells exposed to exogenously-added trypsin undergo changes in morphology, transcriptome, secretome, and developmental potential, and transition into a state of stemness, in minimal essential medium (MEM). Regardless of their origins, i.e., independent of whether they are derived from primary cultures, cell lines or cancer cell lines, and regardless of the original cell type used, exposure to trypsin (∼10 µM; ∼250 µg/ml) at a concentration 10-fold lower than that used to separate cells during passaging (∼100 μM), over a period of 24-48 hours, causes cells to (1) become rounded, (2) cluster together, (3) get arrested in the G0/G1 stage of the cell cycle, (4) display increased presence of 5-hydroxymethyl cytosine in their nuclei (indicative of reprogramming), (5) display increased levels of activated PAR2 membrane receptor, (6) become capable of very efficient efflux of drug-mimicking dyes, (7) express factors and/or markers known to be associated with induction and/or attainment of stemness, with predominant expression of Sox-2 within cell nuclei; (8) display overall transcriptomic (RNASEQ) profiles characteristic of stemness; (9) secrete stemness-associated factors such as bFGF, and IL-1β, into the medium, in quantities sufficient to support autocrine function (in certain cases); and (10) display increased conversion of pro-MMPs into activated MMPs in the cell’s secretome. Notably, (11) inclusion of differentiating and/or transdifferentiating factors in the environment of such cells causes them to express markers associated with ectodermal, endodermal and mesodermal cell lineages and/or transdifferentiate into specific cell types, e.g., adipocytes or osteocytes.Most intriguingly of all, (12) the attained stemness appears to be reversible, i.e., withdrawal of trypsin from the medium prior to addition of any differentiating factors restores cells to their original morphology, also over a period of 24-48 hours. Further, (13) a known PAR2 agonist, and a known PAR2 antagonist, respectively, appear to mimic effects of trypsin addition and withdrawal/inhibition. In addition, (14) in experiments with a particular cancer characterized by high levels of stemness (TNBC; triple negative breast cancer), tissues of all TNBC patients express high levels of the PAR2 receptor, as do cells from a known TNBC-derived cell line. We propose that through their effects on PAR levels, and PAR activation status, the balance of trypsin and A1AT levels in organisms normally regulates cellular potential for differentiation, de-differentiation or transdifferentiation, in a local manner, with the default status being that A1AT inhibits trypsin and keeps cells differentiated, whereas sustained trypsin signaling at sites of injury through local production of trypsin helps to place cells into an intermediate state of stemness from which they can either return to their original differentiated state(s), or undergo factor-dependent differentiation, or transdifferentiation, into specific cell types or lineages. It is also possible that reduction in A1AT promotes regeneration. We present a core (RNASEQ-derived) signature for trypsin-induced stemness in human corneal fibroblasts (HCFs) and cells from a retinal pigment epithelial cell line (ARPE-19), noting that there are commonalities as well as differences between them, which suggests that this core signature will be amended with RNASEQ studies of more trypsin-exposed cell types. Our findings offer a possible explanation for the recent unexplained increase in the preference for serum-free protocols used for induction and maintenance of stemness involving iPSCs and mesenchymal stem cells. Also, our studies suggest a new approach to understanding and exploiting how organisms might use stemness, in adults. Trypsin-dominated serine protease induced reprogramming (SPIR) might offer a more natural, and suitably ‘softer’, method of reprogramming of cellular developmental potential for local regenerative requirements in animal tissues.
The endogenous cellular protease inhibitor SPINT2 controls SARS-CoV-2 viral infection and is associated to disease severity